User profiles for Sophie Park
 | Sophie ParksNSW Department of Primary Industries Verified email at dpi.nsw.gov.au Cited by 1996 |
Developments in medical education in response to the COVID-19 pandemic: a rapid BEME systematic review: BEME Guide No. 63
…, SR Alston, M Pammi, S Thammasitboon, S Park… - Medical …, 2020 - Taylor & Francis
Background The novel coronavirus disease (COVID-19) was declared a pandemic in March
2020. This rapid systematic review synthesised published reports of medical educational …
2020. This rapid systematic review synthesised published reports of medical educational …
An update on developments in medical education in response to the COVID-19 pandemic: a BEME scoping review: BEME Guide No. 64
…, C Pawlik, R Bhagdev, S Ahmad, S Alston, S Park… - Medical …, 2021 - Taylor & Francis
Background COVID-19 has fundamentally altered how education is delivered. Gordon et al.
previously conducted a review of medical education developments in response to COVID-19…
previously conducted a review of medical education developments in response to COVID-19…
Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience
S Park, S Grabar, C Kelaidi… - Blood, The Journal …, 2008 - ashpublications.org
We analyzed prognostic factors of response, response duration, and possible impact on
survival of epoetin α, epoetin β, or darbepoetin α (DAR) with or without granulocyte colony-…
survival of epoetin α, epoetin β, or darbepoetin α (DAR) with or without granulocyte colony-…
Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute …
…, N Chapuis, V Bardet, S Park… - Blood, The Journal …, 2008 - ashpublications.org
The phosphatidylinositol 3-kinase (PI3K)/Akt and mTORC1 pathways are frequently activated,
representing potential therapeutic targets in acute myeloid leukemia (AML). In 19 AML …
representing potential therapeutic targets in acute myeloid leukemia (AML). In 19 AML …
[HTML][HTML] Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an …
…, L Malcovati, M Cazzola, S Park… - Journal of clinical …, 2013 - ncbi.nlm.nih.gov
Purpose Myelodysplastic syndromes (MDS) are clonal hematopoietic disorders that are
more common in patients aged≥ 60 years and are incurable with conventional therapies. …
more common in patients aged≥ 60 years and are incurable with conventional therapies. …
Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: a French multicentre …
…, JE Kahn, M Hamidou, S Park… - …, 2016 - academic.oup.com
Objective. We describe myelodysplastic syndrome (MDS)–associated systemic inflammatory
and autoimmune diseases (SIADs), their treatments and outcomes and the impact of SIADs …
and autoimmune diseases (SIADs), their treatments and outcomes and the impact of SIADs …
The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation
…, C Arnoult, O Boyer, V Bardet, S Park… - Blood, The Journal …, 2010 - ashpublications.org
Finding an effective treatment for acute myeloid leukemia (AML) remains a challenge, and all
cellular processes that are deregulated in AML cells should be considered in the design of …
cellular processes that are deregulated in AML cells should be considered in the design of …
Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia
…, AS Green, V Bardet, N Chapuis, S Park… - Blood, The Journal …, 2009 - ashpublications.org
The deregulation of translation markedly contributes to the malignant phenotype in cancers,
and the assembly of the translation initiating complex eIF4F is the limiting step of this process…
and the assembly of the translation initiating complex eIF4F is the limiting step of this process…
BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders
…, S Miyano, H Mori, LY Shih, S Park… - Blood, The Journal …, 2013 - ashpublications.org
Patients with low-risk myelodysplastic syndromes (MDS) that rapidly progress to acute
myeloid leukemia (AML) remain a challenge in disease management. Using whole-exome …
myeloid leukemia (AML) remain a challenge in disease management. Using whole-exome …
Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia
…, A Neyret, M Pannetier, L Willems, S Park… - Clinical Cancer …, 2010 - AACR
Purpose: The growth and survival of acute myeloid leukemia (AML) cells are enhanced by
the deregulation of signaling pathways such as phosphoinositide 3-kinase (PI3K)/Akt and …
the deregulation of signaling pathways such as phosphoinositide 3-kinase (PI3K)/Akt and …